High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma Authors
Cite this article as: Davidson, B., Goldberg, I., Gotlieb, W.H. et al. Clin Exp Metastasis (1999) 17: 799. doi:10.1023/A:1006723011835 Abstract
The object of this study was to analyze the potential association between the expression of MMP-2, MMP-9, MT1-MMP and TIMP-2, and disease outcome in advanced-stage ovarian carcinomas. Sections from 70 paraffin-embedded blocks (36 primary ovarian carcinomas and 34 metastatic lesions) from 45 patients diagnosed with advanced stage ovarian carcinomas (FIGO stages III–IV) were studied using mRNA
in situ hybridization (ISH) technique. Patients were divided retrospectively in two groups based on disease outcome. Long-term survivors (21 patients) and short-term survivors (24 patients) were defined using a double cut-off of 36 months for disease-free survival (DFS) and 60 months for overall survival (OS). Mean follow-up period for patients that were diagnosed with advanced-stage carcinoma was 70 months. The mean values for DFS and OS were 109 and 125 months for long-term survivors, as compared to 3 and 21 months for short-term survivors, respectively. Intense mRNA signals were detected more frequently in tumor cells of short-term survivors with use of all four probes. Comparable findings were observed in peritumoral stromal cells with ISH for MMP-2, MMP-9 and TIMP-2 mRNA. Notably, primary tumors with intense mRNA signal for TIMP-2 (No = 14) were uniformly associated with a fatal outcome. In univariate analysis of primary tumors, mRNA levels of TIMP-2 in stromal cells ( P = 0.0002), as well as for MMP-9 ( P = 0.012) and TIMP-2 ( P = 0.02) in tumor cells, correlated with poor outcome. In univariate analysis of metastatic lesions, mRNA levels of TIMP-2 in stromal cells ( P = 0.031), as well as for MMP-2 ( P = 0.027) and MT1-MMP ( P = 0.008) in tumor cells, correlated with poor outcome. Interestingly, the presence of MT1-MMP in stromal cells correlated with longer survival ( P = 0.025). In a multivariate analysis of ISH results for primary tumors, TIMP-2 levels in stromal cells ( P = 0.006) and MMP-9 levels in tumor cells ( P = 0.011) retained their predictive value. We conclude that MMP-2, MMP-9, MT1-MMP and TIMP-2 are valid markers of poor survival in advanced-stage ovarian carcinoma. disease outcome MMP-2 MMP-9 MT1-MMP mRNA in situ hybridization ovarian carcinoma
This revised version was published online in July 2006 with corrections to the Cover Date.
Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636–49.
Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997; 91: 439–42.
Crawford HC, Matrisian LN. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994-5; 14: 234–45.
Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1368–83.
Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992; 14: 455–63.
Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 1991; 51: 5054s–5059s (suppl).
Tryggvason K, Höyhtyä M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993; 24: 209–18.
Stetler-Stevenson WG, Liotta LA, Kleiner DE, Jr. Extracellular matrix6: Role of matrix metalloproteinases in tumor invasion and metastasis. Faseb J 1993; 7: 1434–41.
Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J 1991; 5: 2145–54.
Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260–70.
Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 65: 5–27.
Petterson F. International Federation of Gynecology and Obstetrics: Annual report on the results of treatment in gynecological cancer. Stockholm: Panorama Press AB 1995; 83-102, 201–227
Hoskins WJ. Prospective on ovarian cancer: Why prevent? J Cell Biochem 1995; 23: 189–99.
Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 1998; 78: 331–37.
Westerlund A, Hujanen E, Puistola U, Turpeenniemi-Hujanen T. Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa Gelatinase A (MMP-2). Gynecol Oncol 1997; 67: 76–82.
Moore DH, Allison B, Look KY et al. Collagenase expression in ovarian cancer cell lines. Gynecol Oncol 1997; 65: 78–82.
Boyd RS, Balkwill FR. MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J cancer 1999; 80: 315–21.
Höyhtyä M, Fridman R, Komarek D et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994; 56: 500–5.
Takemura M, Azuma C, Kimura T et al. Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues. Int J Gynecol Obstet 1994; 46: 303–9.
Afzal S, Lalani EN, Poulsom R et al. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors. Possible implications for the role of desmoplastic fibroblasts. Hum Pathol 1998; 29: 155–65.
Afzal S, Lalani EN, Foulkes WD et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996; 74: 406–21.
Fishman DA, Bafetti LM, Banionis S et al. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997; 80: 1457–63.
Young TN, Rodriguez GC, Rinehart AR et al. Characterization of Gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2. Gynecol Oncol 1996; 62: 89–99.
Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996; 16: 150–9.
Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994; 58: 50–6.
Campo E, Merino MJ, Tavassoli FA et al. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 1992; 16: 500–7.
Autio-Harmainen H, Karttunen T, Hurskainen T. et al. Expression of 72 kilodalton type IV collagenase (Gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993; 69: 312–21.
Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma (review). Int J Oncol 1998; 12: 569–76.
De Nictolis M, Garbisa S, Lucarini G, et al. 72-KiloDalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors of the ovary: A clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 1996; 15: 102–9.
Garzetti GG, Ciavattini A, Lucarini G et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: Clinical and prognostic implications. Anticancer Res 1995; 15: 2799–804.
Westerlund A, Apaja-Sarkkinen M Höyhtyä M et al. Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999; 75: 91–8.
Zaloudek C. Ovarian neoplasms. In Gompel C, Silverberg SG (eds): Pathology in Gynecology and Obstetrics. Philadelphia: Lippincott 1994; 330–402.
Rosai J. Ackerman's Surgical Pathology. St. Louis: Mosby 1996; 1492–3.
Parks CS, Brigati DJ, Manahan LJ. Automated molecular pathology: one-hour
in-situ DNA hybridization. J Histotechnol 1991; 14: 219–29.
Reed JA, Manahan LJ, Parks CS, Brigati DJ. Complete one-hour immunocytochemistry based on capillary action. Biotechniques 1992; 13: 434–43.
Greene GF, Kitadai Y, Pettaway CA et al. Correlation of metastasisrelated gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 1997; 150: 1571–82.
Davidson B, Goldberg I, Kopolovic J et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999; 73: 372–82.
Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: S42–S51 (Suppl).
Macaulay VM, O'Bryne KJ, Saunders MP et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513–20.
Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999; 43: S61–S68 (Suppl).
Yamamoto H, Itoh F, Adachi Y et al. Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma. Jpn J Clin Oncol 1999; 29: 58–62.
Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133–40.
Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and-9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995; 104: 678–84.
Nuovo GJ, MacConnel PB, Simsir A et al. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 267–75.
Pacheco MM, Mourao M, Mantovani EB et al. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998; 16: 577–85.
Ree AH, Florenes VA, Berg JP et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997; 3: 1623–28.
Kuniyasu H, Ellis LM, Evans DB et al. Relative expression of Ecadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 1999; 5: 25–33.
Caenazzo C, Onisto M, Sartor L et al. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clin Cancer Res 1998; 4: 2179–86.
Sier CF, Kubben FJ, Ganesh S et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413–7.
Kanayama H, Yokota K, Kurokawa Y et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998; 82: 1359–66.
Wood M, Fudge K, Mohler JL et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997; 15: 246–58.
Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10: 31–46.
Grignon DJ, Sakr W, Toth M et al. High levels of tissue inhibitor of metalloproterinase-2 (TIMP-2) are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654–9.
Fishman DA, Kearns A, Chilukuri K et al. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis 1998; 18: 15–26.
Ellerbroek SM, Fishman DA, Kearns A et al. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res 1999; 59: 1635–41.
PubMed Copyright information
© Kluwer Academic Publishers 1999